

10/532452

JC12 Rec'd PCT/PTO 22 APR 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: Based on PCT/JP2003/013528  
Filed: Intl. Filing 23 October 2003  
1<sup>st</sup> Inventor: Yukio SHIMOMURA  
For: Antibody and Utilization of the Same  
Atty. Dkt. No. 3104 USOP

Art Unit: tba  
Examiner: tba  
Allowed:  
Batch:  
Paper No.:

**Information Disclosure Statement**

MAIL STOP PCT  
P.O. Box 1450  
Commissioner for Patents  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.


Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Dated: 

(847) 383-3372  
(847) 383-3391

Respectfully submitted,



Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA

JC12 Rec'd PCT/PTO 22 APR 2005

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number	Based on PCT/JP2003/013528
Filing Date	Intl. Filing 23 October 2003
First Named Inventor	Yukio SHIMOMURA
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3104 USOP

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	A7	WO 03/064646 - Abstract only	08/07/2003	Takeda Chemical Industries		

Date  
Considered

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	Based on PCT/JP2003/013528
Filing Date	Intl. Filing 23 October 2003
First Named Inventor	Yukio SHIMOMURA
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3104 US0P

Sheet 3 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A8	YUTA KOBAYASHI, et al., "Radioimmunoassays for Fish Tail Neuropeptides: II. Development of a Specific and Sensitive Assay for and the Occurrence of Immunoreactive Urotensin II in the Central Nervous System and Blood of Catostomus Commersoni", J. Pharm. Methods, (1986), pp. 321-333, Vol. 15, No. 4	
	A9	KYOKO OWADA, et al., "Urotensin II-immunoreactive Neurons in the Caudal Neurosecretory System of Freshwater and Seawater Fish", Cell and Tissue Research, (1985), pp. 349-354, Vol. 239, No. 2	
	A10	MASAAKI MORI, et al., "Urotensin II is the Endogenous Ligand of a G-Protein-Coupled Orphan Receptor, SENR (GPR14)", Biochemical and Biophysical Research Communications, (1999), pp. 123-129, Vol. 265, No. 1	
	A11	TSUKASA SUGO, et al., "Identification of Urotensin II-Related Peptide as the Urotensin II-Immunoreactive Molecule in the Rat Brain", Biochemical and Biophysical Research Communications, (2003), p. 860-868, Vol. 310, No. 3	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.